Forcing new Frontiers in Molecular Medicine


KCT is a limited company based in Kuopio, Finland that was founded in 2017. We undertake pioneering high-quality basic and translational research in the new and exciting area of Advanced Therapeutic Medicinal Products (ATMPs). Our scientific teams combine scientific know-how gained from years of experience in the sector and the latest technologies to research and develop gene and cell therapy products into Phase I human studies.

We undertake science in collaboration with academic groups all over the world and also have access to FinVector's GMP manufacturing facility in Finland as well as their quality and regulatory teams to ensure a product path from research to patients. KCT’s main therapeutic focuses are cancer and cardiovascular disease, but our scope of interest is not fixed and we also evaluate wider areas, such as neurological dysfunction, for other important therapy approaches.

You must approve to our use of cookies to view this content.

Board of directors

Per Falk, Chairman

Seppo Ylä-Herttuala

Jean-Frédéric Paulsen


Heikki Vuorikoski

Managing Director

Tuija Kekarainen

Scientific Director

Kassim Kolia

Head of Business Development

Olga Gurvich

Analytical Development Manager

Eevi Lipponen

Head of Process Development

(Gene Therapy)

Katja Sirviö

Head of Process Development

(Cell Therapy)

Joonas Malinen

Laboratory Manager

Tiina Nieminen

Gene Therapy Development Manager